Cargando…

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

PURPOSE: The development of blood biomarkers that reflect Alzheimer’s disease (AD) pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests for dementia differential diagnosis and early detection. In 2019, the Geneva AD Biomarker Roadmap Initiative included blood bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V., Hansson, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175325/ https://www.ncbi.nlm.nih.gov/pubmed/33677733 http://dx.doi.org/10.1007/s00259-021-05253-y

Ejemplares similares

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
por: Boccardi, Marina, et al.
Publicado: (2021)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
por: Salvadó, Gemma, et al.
Publicado: (2023)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2021)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K., et al.
Publicado: (2018)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
por: Snellman, Anniina, et al.
Publicado: (2022)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
por: Leuzy, Antoine, et al.
Publicado: (2020)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_stt0q6lbl8e39fg1jqrl2vg53f